Pihlajalinna Oyj:Pihlajalinna and Sentica announce their

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pihlajalinna Oyj:Pihlajalinna and Sentica announce their intention to offer shares in Pihlajalinna to institutional investors

Pihlajalinna Oyj Stock Exchange release 14 December 2015 at 18.50 (EET)

Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, South Africa, or Japan or in any other jurisdiction in which publication or distribution would be prohibited by applicable law.

Pihlajalinna and Sentica announce their intention to offer shares in Pihlajalinna to institutional investors

Pihlajalinna Plc ("Pihlajalinna" or the "Company") intends to offer up to 1,500,000 new shares in the Company (the "Issue Shares") to a limited number of institutional investors in deviation from the shareholders' pre-emptive subscription rights (the "Share Issue"). The Issue Shares offered correspond approximately to 7.8 per cent of all the shares and voting rights in the Company immediately prior to the Share Issue. The Company intends to use the net proceeds from the Share Issue to finance the acquisitions of Tampereen Lääkärikeskus Oy, Röntgentutka Oy and Itä-Suomen Lääkärikeskus Oy announced in December 2015 and other possible acquisitions as well as to support the growth strategy of the Company.

Sentica Buyout III Ky and Sentica Buyout III Co-Investment Ky (together "Sentica") intend to sell shares in Pihlajalinna (the "Sale Shares", together with the Issue Shares the "Shares") in connection with the Share Issue (the "Share Sale"). Sentica will decide the number of Sale Shares based on investor demand. Prior to the Share Sale, Sentica owns 5,035,990 shares in the Company corresponding approximately to 26 per cent of all the outstanding shares of the Company. 

The Share Issue and the Share Sale will be based on an accelerated book-building process, in which selected institutional investors may submit bids for the Shares. The subscription and sale price of the Shares will be determined by the bids received in the accelerated book-building process. The book-building process will commence immediately and will end by 9.00 a.m. EET on 15 December 2015 at the latest. Receiving the bids may however be discontinued at any time during the book-building process. The Board of Directors of Pihlajalinna shall make the decision on the execution of the Share Issue, including the number of the Issue Shares and the subscription price of the Issue Shares, immediately after the close of the book-building process. The subscription and sale price of the Shares will be the same in the Share Issue and the Share Sale, and in the book-building process, Shares are primarily subscribed for in the Share Issue and secondarily in the Share Sale. The result of the Share Issue and the Share Sale will be published on or about 15 December 2015.

The Issue Shares are expected to be registered in the Finnish Trade Register on or about 16 December 2015 and trading in the Issue Shares is expected to commence on Nasdaq Helsinki Ltd on or about 17 December 2015. The Issue Shares will rank pari passu in all respects with the existing shares of the Company, once they have been registered with the Finnish Trade Register. The Share Issue is based on the authorisation to issue new shares in deviation from the shareholders' pre-emptive subscription rights, granted to the Board of Directors by the Annual General Meeting held on 14 December 2015.  

In connection with the Share Issue, Pihlajalinna has entered into a lock-up undertaking, under which it has, subject to certain exceptions, agreed not to issue or sell any shares in Pihlajalinna for a period ending 90 days after the closing of the Share Issue.

Carnegie Investment Bank AB and Danske Bank A/S, Helsinki Branch are acting as Joint Lead Managers in the Share Issue and the Share Sale.

Pihlajalinna Oyj

Board of Directors

Mikko Wiren, CEO

Further information

Mikko Wirén, CEO, Pihlajalinna Plc, 050 322 0927

Mika Uotila, CEO, Sentica Partners Ltd, 040 553 6110

Terhi Kivinen, SVP, Communications, Marketing and IR, Pihlajalinna Plc, +358 40 848 4001, terhi.kivinen@pihlajalinna.fi

Distribution

Nasdaq OMX Helsinki

Key media

investors.pihlajalinna-konserni.fi 

 

Disclaimer

Both Carnegie and Danske Bank are acting exclusively for the Company and no one else and they will not regard any other person (whether or not a recipient of this release) as their respective clients in relation to the Share Issue. Carnegie and Danske Bank will not be responsible to anyone other than Pihlajalinna for providing the protections afforded to their respective clients and will not give advice in relation to the Share Issue or any transaction or arrangement referred to herein. Carnegie and Danske Bank assume no responsibility for the accuracy, completeness or verification of the information set forth in this release and, accordingly, disclaim, to the fullest extent permitted by applicable law, any and all liability which they may otherwise be found to have in respect of this release. Nothing contained in this release is, or shall be relied upon as, a promise or representation as to the past or the future.

The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, South Africa or Japan. This release does not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. There is no intention to register any portion of the Share Issue in the United States or to conduct a public offering of securities in the United States.

The issue, exercise or sale of securities in the Share Issue are subject to specific legal or regulatory restrictions in certain jurisdictions. Pihlajalinna assumes no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

Pihlajalinna has not authorized any offer to the public of securities in any Member State of the European Economic Area. The securities referred to in this release may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto).

This communication is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order) and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as relevant persons). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

 

 

HUG#1973339

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 15

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 19

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 20

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 14

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 19

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 24

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 24

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 18

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 19

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

LightBox CRE Activity Index Sees Positive Response to Rates

Updated Category News Views 67

Introduction to LightBox's Findings Recent insights from LightBox reveal significant shifts in the commercial real estate (CRE) sector, highlighting increased activity in response to recent economic changes. As a leading provider of CRE information and technology, LightBox's Monthly CRE Activity Index plays a crucial role in tracking the dynamics of the market....

Continue Reading
Alliance Pharma's Recent Trading Activity on the LSE Explored

Updated Category News Views 167

Understanding Alliance Pharma's Trading Activity Alliance Pharma plc, known for its strategic positioning in the pharmaceutical market, has made a significant impact through its recent trading activities. These transactions are crucial for understanding the company's current standing and future potential in the market. The firm operates under the stock ticker LSE:INVP,...

Continue Reading
Icon Energy Corp. Welcomes M/V Bravo and Secures Funding

Updated Category News Views 83

Icon Energy Corp. Welcomes M/V Bravo and Secures Financing Icon Energy Corp. (“Icon”) (Nasdaq: ICON) is thrilled to announce the arrival of its latest fleet member, the M/V Bravo, alongside significant financing aimed at facilitating future growth. This advanced Kamsarmax dry bulk carrier represents a key achievement in Icon's operational strategy, paving the way for...

Continue Reading
Coinbase Investor Alert: Class Action Lawsuit Filed Against Company

Updated Category News Views 403

Traders braced for turmoil as Coinbase Global, Inc. (NASDAQ: COIN) found itself entangled in a significant class action lawsuit back in 2024, brought forth by the reputable law firm Bronstein, Gewirtz & Grossman. This isn’t just another legal skirmish; it’s an alarm bell ringing loudly for investors who acquired Coinbase securities during the defined Class Period....

Continue Reading
Danny Go! Launches Exciting New Toy Line with Just Play

Updated Category News Views 447

Danny Go! Launches Exciting New Toy Line Three new active-play toys inspired by the beloved YouTube series, Danny Go!, are set to hit shelves just in time for the holiday season. This innovative collaboration between Danny Go! and Just Play, a prominent toy company, aims to engage children through play, song, and dance. Exciting Toy Debut at Walmart The launch of these...

Continue Reading